What happened with COR today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Cencora buys medicines from manufacturers and sells them to pharmacies, hospitals and physician practices, usually as their primary supplier. Most revenue comes from its U.S. human-health business, which distributes branded, generic and specialty medicines, including treatments administered by doctors. It also supplies healthcare providers in Europe and sells animal-health products.
Providers pay Cencora for the products they buy and for services such as pharmacy management and patient-access support. Pharmaceutical and biotechnology manufacturers also pay for services that help bring medicines to market, meet regulatory requirements and transport specialized products. These services complement the much larger drug-distribution business.
Revenue is concentrated among a relatively small group of large customers. Walgreens and Boots together are its largest customer relationship, and Evernorth Health Services is another major customer. The business depends on retaining these relationships, securing medicines from suppliers and managing the difference between purchase and selling prices as manufacturers change drug prices. Distribution also requires licenses and product traceability; controlled-substance rules and its opioid settlement require monitoring to prevent drugs from being diverted to unauthorized uses.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Cencora’s results hinge on prescription volumes and major customer contracts: Walgreens and Boots together accounted for 25% of fiscal 2025 revenue, and Evernorth Health Services another 13%.
McKesson competes with Cencora for pharmacies, hospitals and physician practices buying branded, generic and specialty medicines. Its specialty-drug distribution and services for oncology and retina practices show where the two also compete beyond supplying medicines.
Cardinal Health competes with Cencora to supply medicines to pharmacies and healthcare providers and sell them related services. Its Pharmaceutical and Specialty Solutions business is the part to watch, covering specialty medicines, hospital pharmacy management and physician-office management.
Demand for Eli Lilly’s diabetes and weight-loss medicines drives drug volumes through Cencora, which buys medicines from Lilly and distributes them to pharmacies and healthcare providers. Lilly makes and sells these treatments, so demand for them is the connection to watch for Cencora’s distribution business.
Eli Lilly & Co. earningsLLY
Eli Lilly's report will show whether demand for its diabetes and weight-loss medicines is still driving drug volume through Cencora to pharmacies and healthcare providers.
Look for Lilly's account of demand and sales for these medicines. Stronger demand can send more product through Cencora to pharmacies and providers, supporting distribution volume; weaker demand removes some of that volume support. More volume does not mean proportionately more profit: Cencora has said higher sales of lower-margin GLP-1 products weighed on its U.S. gross margin.
Cencora, Inc. earningsThis company
Cencora's report will show whether growth in distributed drug sales is translating into higher gross profit, especially in U.S. Human Health.
Compare U.S. Human Health sales with its gross profit. If gross profit grows faster than sales, Cencora is keeping more profit from each dollar distributed, possibly reflecting a richer mix of generics or other higher-margin business. If sales grow but gross profit lags, more product is moving without a comparable improvement in profit captured per sales dollar.
McKesson Corporation earningsMCK
McKesson's report will show whether pharmacies, hospitals and physician practices it shares with Cencora are sustaining demand for drug distribution and specialty services, including oncology and retina care.
Check whether McKesson's pharmaceutical distribution and oncology and retina businesses grow, and read sales alongside service volumes and profit. Strength would show demand holding up among pharmacies, hospitals and practices where the companies compete; weakness would signal pressure in shared customer and specialty channels, potentially weighing on Cencora's volume or services, though McKesson's results cannot establish Cencora's own performance.
